PH12020500044A1 - Aav vector column purification methods - Google Patents

Aav vector column purification methods

Info

Publication number
PH12020500044A1
PH12020500044A1 PH12020500044A PH12020500044A PH12020500044A1 PH 12020500044 A1 PH12020500044 A1 PH 12020500044A1 PH 12020500044 A PH12020500044 A PH 12020500044A PH 12020500044 A PH12020500044 A PH 12020500044A PH 12020500044 A1 PH12020500044 A1 PH 12020500044A1
Authority
PH
Philippines
Prior art keywords
purification methods
aav vector
column purification
chromatography
vector column
Prior art date
Application number
PH12020500044A
Other languages
English (en)
Inventor
Younghoon Oh
Guang Qu
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Publication of PH12020500044A1 publication Critical patent/PH12020500044A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PH12020500044A 2017-06-30 2020-01-03 Aav vector column purification methods PH12020500044A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762527633P 2017-06-30 2017-06-30
US201762531744P 2017-07-12 2017-07-12
US201762567905P 2017-10-04 2017-10-04
PCT/US2018/040430 WO2019006390A1 (en) 2017-06-30 2018-06-29 AAV VECTOR COLUMN PURIFICATION METHOD

Publications (1)

Publication Number Publication Date
PH12020500044A1 true PH12020500044A1 (en) 2020-09-14

Family

ID=64742749

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020500044A PH12020500044A1 (en) 2017-06-30 2020-01-03 Aav vector column purification methods

Country Status (16)

Country Link
US (1) US20210079422A1 (cg-RX-API-DMAC7.html)
EP (1) EP3658250A4 (cg-RX-API-DMAC7.html)
JP (3) JP2020526190A (cg-RX-API-DMAC7.html)
KR (2) KR102879640B1 (cg-RX-API-DMAC7.html)
CN (1) CN111032176A (cg-RX-API-DMAC7.html)
AU (1) AU2018291023B2 (cg-RX-API-DMAC7.html)
CA (1) CA3068622A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003915A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020000911A2 (cg-RX-API-DMAC7.html)
IL (1) IL271745A (cg-RX-API-DMAC7.html)
MX (2) MX2020000216A (cg-RX-API-DMAC7.html)
MY (1) MY207534A (cg-RX-API-DMAC7.html)
PE (2) PE20251545A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500044A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201913157RA (cg-RX-API-DMAC7.html)
WO (1) WO2019006390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
ES2965341T3 (es) 2019-04-11 2024-04-12 Regenxbio Inc Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
EP3919613B1 (en) * 2020-06-05 2024-08-07 Sartorius BIA Separations d.o.o. Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
JP2023537565A (ja) * 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第viii因子を除去する方法
US20220033782A1 (en) * 2020-07-29 2022-02-03 Pall Corporation Adenovirus-associated viruses separation method
US20220154223A1 (en) 2020-10-15 2022-05-19 Hoffmann-La Roche Inc. Nucleic acid constructs for simultaneous gene activation
WO2022079083A1 (en) 2020-10-15 2022-04-21 F. Hoffmann-La Roche Ag Nucleic acid constructs for va rna transcription
JP7767029B2 (ja) * 2021-05-28 2025-11-11 ダイセン・メンブレン・システムズ株式会社 細胞外小胞の分離精製方法
JP7716233B2 (ja) * 2021-05-28 2025-07-31 ダイセン・メンブレン・システムズ株式会社 微小有用物質の分離精製方法と分離精製装置
BR112023025999A2 (pt) * 2021-06-11 2024-02-27 Spark Therapeutics Inc Métodos de purificação de coluna de vetor de aav
WO2023023541A1 (en) * 2021-08-17 2023-02-23 Ultragenyx Pharmaceutical Inc. Anion-exchange chromatography methods for purification of recombinant adeno-associated viruses
EP4408857A4 (en) * 2021-09-28 2025-11-05 Kashiv Biosciences Llc IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN
CN114250222A (zh) * 2021-12-08 2022-03-29 苏州博腾生物制药有限公司 一种从动物组织中提取aav dna的方法
GB202117844D0 (en) * 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
JP7898711B2 (ja) * 2022-03-24 2026-08-03 国立大学法人 東京大学 ウイルスの精製方法
EP4508241A1 (en) 2022-04-13 2025-02-19 F. Hoffmann-La Roche AG Method for determining aav genomes
EP4529614A1 (en) 2022-05-23 2025-04-02 F. Hoffmann-La Roche AG Raman-based method for the differentiation of aav particle serotype and aav particle loading status
JP2025519228A (ja) 2022-06-03 2025-06-24 エフ. ホフマン-ラ ロシュ アーゲー 組換えaav粒子を生成するための方法
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024024337A1 (ja) * 2022-07-28 2024-02-01 株式会社ダイセル 微小有用物質を含む液の精製濃縮装置及びそれを用いた微小有用物質を含む精製濃縮液の製造方法
JP2025530294A (ja) 2022-09-12 2025-09-11 エフ. ホフマン-ラ ロシュ アーゲー 完全なaav粒子と空のaav粒子を分離するための方法
EP4385618A1 (en) 2022-12-16 2024-06-19 Chiral Technologies Europe SAS Composite material for bioseparations
AU2024216670A1 (en) 2023-02-07 2025-07-31 F. Hoffmann-La Roche Ag Method for the detection of anti-aav particle antibodies
WO2024194280A1 (en) 2023-03-21 2024-09-26 F. Hoffmann-La Roche Ag Method for the production of recombinant aav particle preparations
EP4694994A1 (en) * 2023-04-12 2026-02-18 Cytiva BioProcess R&D AB A chromatography system, use thereof, and a method for separating adeno-associated capsids
AU2025218748A1 (en) 2024-02-09 2026-08-06 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025217029A1 (en) * 2024-04-07 2025-10-16 Spark Therapeutics, Inc. Compositions & methods for adeno-associated virus capsid variant purification
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
US20260022401A1 (en) 2024-07-22 2026-01-22 Hoffmann-La Roche Inc. Novel AAV rep ORFs and Rep polypeptides
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles
WO2026132139A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Purification process for viral vectors
WO2026132012A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Aav particle processing using affinity chromatography with gradient elution

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
JP4559429B2 (ja) * 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
JP5956331B2 (ja) * 2009-06-16 2016-07-27 ジェンザイム・コーポレーション 組換えaavベクターの改良された精製方法
EP2529020B1 (en) * 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
EP3384015A4 (en) * 2015-12-01 2019-05-29 Spark Therapeutics, Inc. SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION
US11015174B2 (en) * 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV8
WO2017100674A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
EP3992283A1 (en) * 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
PH12018502104B1 (en) * 2016-03-31 2024-03-27 Spark Therapeutics Inc Column-based fully scalable raav manufacturing process

Also Published As

Publication number Publication date
MX2024007103A (es) 2024-06-24
PE20251545A1 (es) 2025-06-05
MY207534A (en) 2025-03-03
JP2025038906A (ja) 2025-03-19
RU2020103743A (ru) 2021-07-30
KR20240093848A (ko) 2024-06-24
CO2020000911A2 (es) 2020-06-19
WO2019006390A1 (en) 2019-01-03
KR102879640B1 (ko) 2025-10-30
RU2020103743A3 (cg-RX-API-DMAC7.html) 2021-09-30
CN111032176A (zh) 2020-04-17
KR102669561B1 (ko) 2024-05-24
EP3658250A4 (en) 2021-10-27
AU2018291023B2 (en) 2023-11-02
PE20200737A1 (es) 2020-07-23
BR112019028299A2 (pt) 2020-07-14
US20210079422A1 (en) 2021-03-18
JP2023029832A (ja) 2023-03-07
CL2019003915A1 (es) 2020-06-19
JP2020526190A (ja) 2020-08-31
IL271745A (en) 2020-02-27
EP3658250A1 (en) 2020-06-03
CA3068622A1 (en) 2019-01-03
AU2018291023A1 (en) 2020-02-06
SG11201913157RA (en) 2020-01-30
KR20200040749A (ko) 2020-04-20
MX2020000216A (es) 2020-09-03

Similar Documents

Publication Publication Date Title
MX2020000216A (es) Metodos de purificacion por columna de vectores aav.
WO2019241535A3 (en) Anion exchange chromatography for recombinant aav production
PH12018502104A1 (en) Column-based fully scalable raav manufacturing process
MX2020006884A (es) Metodos de purificacion de virus adenoasociado.
AU2018260998A2 (en) Modulatory polynucleotides
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
WO2016164609A3 (en) Production of oversized adeno-associated vectors
HK1254337A1 (zh) April的抗体分子及其用途
MY205689A (en) Antibody molecules to cd138 and uses thereof
PH12022551228A1 (en) Trem2 antibodies and uses thereof
MX2025009320A (es) Anticuerpos anti-cd19 novedosos
MX2023007810A (es) Compuestos de complejo de hierro para uso terapeutico.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2023005041A (es) Proceso para enriquecer virus adenoasociado.
EP4273165A3 (en) Interferon beta antibodies and uses thereof
MX2019008996A (es) Composiciones y metodos para reducir la carga biologica en cromatografia.
MX2015011994A (es) Eliminacion de ligandos lixiviados de purificacion de afinidad.
WO2017083491A3 (en) Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
Bertapelle et al. On the perfection of schemes
MX2016010968A (es) Unidad de muelle de soporte de suspension para un chasis de vehiculo.
HK40049496A (en) Anion exchange chromatography for recombinant aav production
Сисоєва Methodological standards comparative studies in education in the Polish scientific space
PT3245217T (pt) 3.alfa.-etinil, 3.beta.-hidroxi-5.alfa.-pregnan-20-oxima para utilização no tratamento de transtornos do snc
TH155906S (th) ยางรถยนต์
TH65982S1 (th) ยางรถยนต์